CN102448980B - C6orf167肽及包含它的疫苗 - Google Patents

C6orf167肽及包含它的疫苗 Download PDF

Info

Publication number
CN102448980B
CN102448980B CN201080024056.0A CN201080024056A CN102448980B CN 102448980 B CN102448980 B CN 102448980B CN 201080024056 A CN201080024056 A CN 201080024056A CN 102448980 B CN102448980 B CN 102448980B
Authority
CN
China
Prior art keywords
c6orf167
seq
peptide
cancer
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080024056.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102448980A (zh
Inventor
中村佑辅
醍醐弥太郎
角田卓也
大泽龙司
吉村祥子
渡边朝久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Priority to CN201510111822.1A priority Critical patent/CN104774260A/zh
Publication of CN102448980A publication Critical patent/CN102448980A/zh
Application granted granted Critical
Publication of CN102448980B publication Critical patent/CN102448980B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
CN201080024056.0A 2009-04-01 2010-03-31 C6orf167肽及包含它的疫苗 Expired - Fee Related CN102448980B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510111822.1A CN104774260A (zh) 2009-04-01 2010-03-31 C6orf167肽及包含它的疫苗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21170009P 2009-04-01 2009-04-01
US61/211,700 2009-04-01
PCT/JP2010/002352 WO2010113495A1 (en) 2009-04-01 2010-03-31 C6orf167 peptides and vaccines containing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510111822.1A Division CN104774260A (zh) 2009-04-01 2010-03-31 C6orf167肽及包含它的疫苗

Publications (2)

Publication Number Publication Date
CN102448980A CN102448980A (zh) 2012-05-09
CN102448980B true CN102448980B (zh) 2015-04-15

Family

ID=42827803

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080024056.0A Expired - Fee Related CN102448980B (zh) 2009-04-01 2010-03-31 C6orf167肽及包含它的疫苗
CN201510111822.1A Pending CN104774260A (zh) 2009-04-01 2010-03-31 C6orf167肽及包含它的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510111822.1A Pending CN104774260A (zh) 2009-04-01 2010-03-31 C6orf167肽及包含它的疫苗

Country Status (14)

Country Link
US (1) US20120128705A1 (enExample)
EP (1) EP2414383A4 (enExample)
JP (1) JP5728759B2 (enExample)
KR (1) KR20120034605A (enExample)
CN (2) CN102448980B (enExample)
AU (1) AU2010231381A1 (enExample)
BR (1) BRPI1013384A2 (enExample)
CA (1) CA2757210A1 (enExample)
IL (1) IL215268A0 (enExample)
MX (1) MX2011010191A (enExample)
RU (1) RU2011144088A (enExample)
SG (2) SG2014011423A (enExample)
TW (1) TW201100090A (enExample)
WO (1) WO2010113495A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013671A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
CN102884190B (zh) 2010-03-11 2016-03-23 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
JP2013542711A (ja) * 2010-08-19 2013-11-28 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのＣ６ｏｒｆ１６７

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins
CN1694901A (zh) * 2002-09-12 2005-11-09 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US20080207497A1 (en) * 2000-12-04 2008-08-28 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1351069A (zh) * 2000-10-26 2002-05-29 上海博德基因开发有限公司 一种新的多肽——鼠的同ampa受体相互作用的蛋白grip12.54和编码这种多肽的多核苷酸
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
DK2325306T3 (en) * 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2295571A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5409658B2 (ja) * 2008-03-13 2014-02-05 セレラ コーポレーション 静脈血栓症に関連した遺伝子多型、その検出方法および使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins
US20080207497A1 (en) * 2000-12-04 2008-08-28 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN1694901A (zh) * 2002-09-12 2005-11-09 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗

Also Published As

Publication number Publication date
WO2010113495A1 (en) 2010-10-07
SG174998A1 (en) 2011-11-28
EP2414383A4 (en) 2013-07-31
TW201100090A (en) 2011-01-01
EP2414383A1 (en) 2012-02-08
CN104774260A (zh) 2015-07-15
BRPI1013384A2 (pt) 2016-03-29
CA2757210A1 (en) 2010-10-07
US20120128705A1 (en) 2012-05-24
CN102448980A (zh) 2012-05-09
MX2011010191A (es) 2011-11-29
RU2011144088A (ru) 2013-05-10
JP5728759B2 (ja) 2015-06-03
KR20120034605A (ko) 2012-04-12
AU2010231381A1 (en) 2011-11-03
JP2012522488A (ja) 2012-09-27
IL215268A0 (en) 2011-11-30
SG2014011423A (en) 2014-05-29

Similar Documents

Publication Publication Date Title
CN102356155B (zh) Neil3肽及包含它的疫苗
CN105164256B (zh) Kntc2肽及包含它们的疫苗
CN104066746B (zh) Topk肽及包含它们的疫苗
CN102947325B (zh) Cdca5肽及包含它们的疫苗
CN102822193B (zh) 修饰的melk肽及包含它们的疫苗
CN103732743B (zh) Mphosph1肽及包含它们的疫苗
CN103620033A (zh) Sema5b肽及包含它们的疫苗
CN102459314B (zh) Ttk肽及包含它们的疫苗
CN103339253B (zh) Tomm34肽及包含它们的疫苗
CN102448980B (zh) C6orf167肽及包含它的疫苗
CN102939379B (zh) Ect2肽及包含它们的疫苗
CN103189510B (zh) Ttll4肽及包含它们的疫苗
CN102884190B (zh) Hjurp肽及包含它们的疫苗
CN102753567A (zh) Mybl2肽及包含它们的疫苗
CN102770441A (zh) Tmem22肽及包含它们的疫苗
CN103282494B (zh) C18orf54肽及包含它们的疫苗
CN103270156B (zh) Wdhd1肽及包含它们的疫苗
CN105814073A (zh) Sema5b肽和含有sema5b肽的疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150415

Termination date: 20160331

CF01 Termination of patent right due to non-payment of annual fee